CA1073353A - Sulphonamide/potentiator solutions - Google Patents

Sulphonamide/potentiator solutions

Info

Publication number: CA1073353A
Authority: CA; Canada
Prior art keywords: weight; solution; solutions; sulphonamide; potentiator
Prior art date: 1976-06-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA280,759A

Other languages

English (en)

French (fr)

Inventor

Helmut Franz

Klaus Stoll

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Saarstickstoff-Fatol GmbH

Original Assignee

Saarstickstoff-Fatol GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-06-21

Filing date

1977-06-17

Publication date

1980-03-11

1977-06-17 Application filed by Saarstickstoff-Fatol GmbH filed Critical Saarstickstoff-Fatol GmbH

1980-03-11 Application granted granted Critical

1980-03-11 Publication of CA1073353A publication Critical patent/CA1073353A/en

Status Expired legal-status Critical Current

Links

229940124530 sulfonamide Drugs 0.000 title claims abstract description 16
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title claims abstract description 15
229940074076 glycerol formal Drugs 0.000 claims abstract description 31
239000004480 active ingredient Substances 0.000 claims abstract description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
230000007935 neutral effect Effects 0.000 claims abstract description 10
239000000203 mixture Substances 0.000 claims abstract description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 8
239000002904 solvent Substances 0.000 claims abstract description 8
-1 amine salt Chemical class 0.000 claims abstract description 7
239000002253 acid Substances 0.000 claims abstract description 6
235000020354 squash Nutrition 0.000 claims abstract description 6
229910052783 alkali metal Inorganic materials 0.000 claims abstract description 5
150000001340 alkali metals Chemical class 0.000 claims abstract description 4
239000008365 aqueous carrier Substances 0.000 claims abstract description 4
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical group COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 11
235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
239000000796 flavoring agent Substances 0.000 claims description 5
235000019634 flavors Nutrition 0.000 claims description 5
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
229920001400 block copolymer Polymers 0.000 claims description 4
229940117927 ethylene oxide Drugs 0.000 claims description 4
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 3
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical group NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims description 2
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
238000006243 chemical reaction Methods 0.000 abstract description 6
238000001802 infusion Methods 0.000 abstract description 5
239000000243 solution Substances 0.000 description 39
238000002360 preparation method Methods 0.000 description 14
229960005404 sulfamethoxazole Drugs 0.000 description 10
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 10
229960001082 trimethoprim Drugs 0.000 description 10
235000008504 concentrate Nutrition 0.000 description 8
239000012141 concentrate Substances 0.000 description 8
235000019441 ethanol Nutrition 0.000 description 7
229960004756 ethanol Drugs 0.000 description 7
235000002639 sodium chloride Nutrition 0.000 description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
239000000725 suspension Substances 0.000 description 5
229960004418 trolamine Drugs 0.000 description 5
235000003599 food sweetener Nutrition 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
150000003456 sulfonamides Chemical class 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000006188 syrup Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
LDBTVAXGKYIFHO-UHFFFAOYSA-N diaveridine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=CN=C(N)N=C1N LDBTVAXGKYIFHO-UHFFFAOYSA-N 0.000 description 3
239000003978 infusion fluid Substances 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
229950000246 diaveridine Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
229960001462 sodium cyclamate Drugs 0.000 description 2
229960004025 sodium salicylate Drugs 0.000 description 2
CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VCKSNYNNVSOWEE-UHFFFAOYSA-N 1,3-dioxan-5-ol Chemical compound OC1COCOC1 VCKSNYNNVSOWEE-UHFFFAOYSA-N 0.000 description 1
BOHGAOWOIJMTPZ-UHFFFAOYSA-N 1,3-dioxolan-4-ylmethanol Chemical compound OCC1COCO1 BOHGAOWOIJMTPZ-UHFFFAOYSA-N 0.000 description 1
KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
RJQQOKKINHMXIM-UHFFFAOYSA-N 2-hydroxypropanoate;tris(2-hydroxyethyl)azanium Chemical compound CC(O)C(O)=O.OCCN(CCO)CCO RJQQOKKINHMXIM-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
KEEYRKYKLYARHO-UHFFFAOYSA-N 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC(C)=C1CC1=CN=C(N)N=C1N KEEYRKYKLYARHO-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
235000012550 Pimpinella anisum Nutrition 0.000 description 1
240000004760 Pimpinella anisum Species 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960003068 ormetoprim Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
235000019640 taste Nutrition 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229940062461 triethanolamine lactate Drugs 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA280,759A 1976-06-21 1977-06-17 Sulphonamide/potentiator solutions Expired CA1073353A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2627706A DE2627706C2 (de)	1976-06-21	1976-06-21	Verfahren zur Herstellung von neutralen beständigen, mit Wasser zu klaren Lösungen verdünnbaren Sulfonamid-Potentiatorlösungen

Publications (1)

Publication Number	Publication Date
CA1073353A true CA1073353A (en)	1980-03-11

Family

ID=5981032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA280,759A Expired CA1073353A (en)	1976-06-21	1977-06-17	Sulphonamide/potentiator solutions

Country Status (11)

Country	Link
JP (1)	JPS533513A (da)
AU (1)	AU514197B2 (da)
BE (1)	BE855687A (da)
CA (1)	CA1073353A (da)
DE (1)	DE2627706C2 (da)
DK (1)	DK143997C (da)
FR (1)	FR2355503A1 (da)
GB (1)	GB1540177A (da)
NL (1)	NL7706841A (da)
NO (1)	NO772167L (da)
SE (1)	SE7706807L (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2631780C3 (de) *	1976-07-15	1981-11-19	Basf Ag, 6700 Ludwigshafen	Sulfonamid-Trimethoprim-Lösungen
DE2963584D1 (en) *	1978-08-01	1982-10-21	Ciba Geigy Ag	Stable, liquid pharmaceutical formulation, its preparation and use
IE49933B1 (en) *	1979-07-05	1986-01-08	Pfizer	Sulfonamide solutions
CN114129510A (zh) *	2021-12-03	2022-03-04	聊城大学	一种复方磺胺注射剂及制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1044231B (it) *	1972-03-16	1980-03-20	Hoffmann La Roche	Combinazione di sostanze attive utile per combattere infezioni da batteri gram positivi e gran negativi

1976
- 1976-06-21 DE DE2627706A patent/DE2627706C2/de not_active Expired
1977
- 1977-06-13 SE SE7706807A patent/SE7706807L/xx unknown
- 1977-06-14 BE BE178447A patent/BE855687A/xx not_active IP Right Cessation
- 1977-06-17 AU AU26179/77A patent/AU514197B2/en not_active Expired
- 1977-06-17 CA CA280,759A patent/CA1073353A/en not_active Expired
- 1977-06-20 JP JP7377477A patent/JPS533513A/ja active Pending
- 1977-06-20 NO NO772167A patent/NO772167L/no unknown
- 1977-06-21 DK DK273677A patent/DK143997C/da active
- 1977-06-21 GB GB25987/77A patent/GB1540177A/en not_active Expired
- 1977-06-21 FR FR7718921A patent/FR2355503A1/fr active Granted
- 1977-06-21 NL NL7706841A patent/NL7706841A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
DK143997B (da)	1981-11-16
FR2355503A1 (fr)	1978-01-20
AU2617977A (en)	1978-12-21
SE7706807L (sv)	1977-12-22
DK143997C (da)	1982-04-19
DE2627706C2 (de)	1982-11-18
FR2355503B1 (da)	1980-06-27
DK273677A (da)	1977-12-22
BE855687A (fr)	1977-10-03
NL7706841A (nl)	1977-12-23
AU514197B2 (en)	1981-01-29
GB1540177A (en)	1979-02-07
JPS533513A (en)	1978-01-13
NO772167L (no)	1977-12-22
DE2627706A1 (de)	1977-12-22

Legal Events

Date	Code	Title	Description
1997-03-11	MKEX	Expiry

Publication	Publication Date	Title
US3985876A (en)	1976-10-12	Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine
US6410543B1 (en)	2002-06-25	Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution
US4861786A (en)	1989-08-29	Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use
HU229372B1 (en)	2013-11-28	Pharmaceutical dronedarone composition for parenteral administration
US4031214A (en)	1977-06-21	Sulphonamide and 2,4-diaminopyrimidine injectable suspension
KR102872122B1 (ko)	2025-10-16	다회-사용 토라세미드 조성물
JP3129428B2 (ja)	2001-01-29	セファロスポリン系薬物を含有する注射用組成物
US8445457B2 (en)	2013-05-21	Oral pharmaceutical solutions containing telbivudine
RU2363462C2 (ru)	2009-08-10	Фармацевтическая композиция, содержащая 5-метил-2-(2′-хлор-6′-фторанилин)фенилуксусную кислоту
US4880796A (en)	1989-11-14	Antimicrobial preparation
US5886018A (en)	1999-03-23	Pharmaceutical composition for parenteral administration containing an indole-carboxylic acid
EP1646393B1 (en)	2013-09-04	A stable clozapine suspension formulation
NO140578B (no)	1979-06-25	Fremgangsmaate til fremstilling av en klar injiserbar opploesning
DK159376B (da)	1990-10-08	Fremgangsmaade til fremstilling af et stabilt, fast, vandoploeseligt praeparat til rekonstituering med vand eller en vandig baerer som en stabil oploesning af 4'-(9-acridinylamino)methan-sulfon-m-anisid
EP0893121B1 (en)	2002-03-13	Oral liquid medicine solution
US3155587A (en)	1964-11-03	Stable liquid preparations of 7-chlorotetracycline
DK143997B (da)	1981-11-16	Fremgangsmaade til stabilisering af sulfonamid/potentiatoroploesninger
KR840002014B1 (ko)	1984-11-05	약학적 제제의 제조방법
CA1176562A (en)	1984-10-23	Process for the manufacture of sulfonamide- potentiator solutions
KR0156929B1 (ko)	1998-11-16	안정화된수용성펜타미딘염수용액
US2888381A (en)	1959-05-26	Solutions of citrus bioflavonoids
JP2536173B2 (ja)	1996-09-18	注射剤
US6818662B2 (en)	2004-11-16	Pharmaceutical composition
US6800631B2 (en)	2004-10-05	Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution
US4089968A (en)	1978-05-16	Stable solutions of ipronidazole